STOCK TITAN

Tenaya Therapeutics to Participate in Upcoming Piper Sandler 34th Annual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

SOUTH SAN FRANCISCO, Calif., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Tenaya management will participate in the Piper Sandler 34th Annual Healthcare Conference, taking place in New York, NY, from November 29th to December 1st.

Details of Tenaya’s participation are as follows:

Panel Discussion: Heart to Heart with CV Players to Discuss 2023 Outlook
Date: November 29, 2022
Time: 2:30 – 3:25 p.m. ET

Fireside Chat
Date: November 30, 2022
Time: 8:30 – 8:55 a.m. ET

A webcast of the Piper Sandler event will be available by visiting the Investors section of Tenaya’s website. A replay of the webcast will be available on the Tenaya website for approximately 30 days following the conference.

About Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver curative therapies that address the underlying drivers of heart disease. Founded by leading cardiovascular scientists from Gladstone Institutes and the University of Texas Southwestern Medical Center, Tenaya is developing therapies for rare genetic cardiovascular disorders, as well as for more prevalent heart conditions, through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. For more information, visit www.tenayatherapeutics.com.

Contacts
Investors
Michelle Corral
Vice President, Investor Relations and
Corporate Communications
Tenaya Therapeutics
IR@tenayathera.com
 Media
Wendy Ryan
Ten Bridge Communications
wendy@tenbridgecommunications.com



Tenaya Therapeutics, Inc.

NASDAQ:TNYA

TNYA Rankings

TNYA Latest News

TNYA Stock Data

367.46M
42.73M
1.53%
77.18%
3.93%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
SOUTH SAN FRANCISCO

About TNYA

tenaya therapeutics is a privately-held biopharmaceutical company backed by the column group. the company was founded in 2016 by world-leading scientists from the gladstone institute’s cardiovascular division and the university of texas southwestern medical center. tenaya is dedicated to addressing heart failure through multipronged efforts that target the fundamental cellular pathologies present in diseased cardiac muscle and that leverage cutting-edge research in cardiac development and regeneration. tenaya has a lead gene therapy program focused on in vivo reprogramming of cardiac fibroblasts to cardiomyocytes to regenerate heart tissue, and additional programs focused on cardiomyopathies.